Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Recruiting 4

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Head & Neck 4

Conditions

Squamous Cell Carcinoma of Head and Neck 28Head and Neck Neoplasms 16Mouth Neoplasms 13Oropharyngeal Neoplasms 11Salivary Gland Neoplasms 10Melanoma 7Laryngeal Neoplasms 7Thyroid Neoplasms 6Uterine Cervical Neoplasms 5Hypopharyngeal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Carcinoma 5Breast Neoplasms 5Neoplasm Metastasis 4Nasopharyngeal Carcinoma 4Esophageal Neoplasms 4Endometrial Neoplasms 4Urinary Bladder Neoplasms 3Tongue Neoplasms 3Stomach Neoplasms 3Precancerous Conditions 3Neoplasms 3Lung Neoplasms 3Leukoplakia, Oral 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Triple Negative Breast Neoplasms 2Skin Neoplasms 2Recurrence 2Rectal Neoplasms 2

Interventions

Cisplatin 127Gemcitabine 71Radiotherapy, Intensity-Modulated 61toripalimab 39Capecitabine 37Docetaxel 36Fluorouracil 35Radiotherapy 24camrelizumab 23Drug Therapy 22nimotuzumab 18spartalizumab 13pembrolizumab 13nedaplatin 12Chemoradiotherapy 12sintilimab 11apatinib 11Induction Chemotherapy 11Immune Checkpoint Inhibitors 11tislelizumab 10Nivolumab 10Magnetic Resonance Spectroscopy 10Specimen Handling 9Radiation 9Cetuximab 9Carboplatin 9endostar protein 8Paclitaxel 8Bevacizumab 8anlotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × Biopsy × Head & Neck × Clear all
NCT06064097 2026-06-03

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

National Cancer Institute (NCI)

Phase 2 Recruiting
50 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT06980038 2026-06-01

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

NCT06870435 2025-03-11

Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas

Sun Yat-sen University

Phase NA Recruiting
68,649 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT04085900 2023-07-13

Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City

Zhongshan People's Hospital, Guangdong, China

Recruiting
40,000 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡